Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Opening Session Panel Discussion

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Peter Clark, MA, MD, FRCP: A Payer Perspective

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Opening Session Panel Discussion

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Amit Sanyal, MD: A Clinician’s Perspective

Inavolisib-Based Regimen in PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer

GLP-1 RAs May Lower Risk of Obesity-Related Cancers

Extensive-Stage SCLC Lurbinectedin and Atezolizumab

Use of AI Assistance to Improve HER2 Breast Cancer Classifications

WGS Liquid Biopsies for HPV-Associated Head and Neck Squamous Cell Carcinoma